Icon Plc $ICLR Shares Sold by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP decreased its position in Icon Plc (NASDAQ:ICLR) by 4.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 345,828 shares of the medical research company’s stock after selling 16,084 shares during the period. Westfield Capital Management Co. LP owned approximately 0.43% of Icon worth $50,301,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the company. SVB Wealth LLC purchased a new position in shares of Icon in the first quarter worth about $28,000. Ameritas Advisory Services LLC acquired a new position in Icon in the 2nd quarter worth approximately $48,000. LRI Investments LLC purchased a new position in Icon during the 2nd quarter worth approximately $49,000. Blue Trust Inc. lifted its stake in Icon by 44.0% during the 2nd quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after acquiring an additional 120 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Icon by 40,800.0% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock valued at $59,000 after acquiring an additional 408 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on ICLR shares. Zacks Research cut shares of Icon from a “hold” rating to a “strong sell” rating in a report on Monday, October 27th. Rothschild Redb upgraded Icon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. Mizuho boosted their price target on Icon from $173.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. TD Cowen dropped their price objective on shares of Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a research note on Friday, October 24th. Finally, Baird R W raised shares of Icon from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $205.00.

Icon Trading Down 0.4%

Shares of NASDAQ:ICLR opened at $158.12 on Friday. The business’s 50 day moving average price is $174.45 and its 200-day moving average price is $161.12. Icon Plc has a 1 year low of $125.10 and a 1 year high of $228.29. The firm has a market capitalization of $12.77 billion, a price-to-earnings ratio of 21.40, a price-to-earnings-growth ratio of 3.04 and a beta of 1.22. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $3.31 EPS for the quarter, topping the consensus estimate of $3.28 by $0.03. The company had revenue of $2.04 billion during the quarter, compared to analyst estimates of $1.98 billion. Icon had a net margin of 7.40% and a return on equity of 10.58%. The firm’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.35 EPS. On average, equities research analysts forecast that Icon Plc will post 13.38 earnings per share for the current fiscal year.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.